AbbVie has invested $335 million upfront in a strategic collaboration with ADARx Pharmaceuticals to develop small interfering RNA therapeutics across neuroscience, immunology, and oncology.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.